Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.
The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial
Canadian firm presents FDA with its third biosimilar application.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.
Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.
Swiss drugmaker Novartis received an FDA nod for rare disease treatment Signifor LAR Tuesday, as orphan drug approvals reach new heights.
The new approach shows "The Talk" has a sequel.
Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.
The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
Judge rules Actavis must keep Alzheimer's drug on the market; Wyeth CEO joins Roche board, dispelling rumors he may be next Sanofi CEO; Two senators propose new FDA designation which would award 15 years of marketing exclusivity.
Cubist is re-launching its C.-Diff. antibiotic in an effort to jumpstart sales beyond Cubicin, which contributes most of its product revenue.
Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.
Researchers found no difference between Lyrica (pregabalin) and placebo in treating lumbar spinal stenosis.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.
Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.
An investigational JAK inhibitor, baricitinib, bested placebo in moderate to severe plaque psoriasis in a Phase-III trial.
Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.
GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.
Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.
Jakafi becomes the first drug approved for treating polycythemia vera.
Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.
Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.
CureClick, TrialReach and WEGO team to leverage health communities and speed trial recruitment.
The drugmaker inked a deal with Zosano worth up to $440 million for the product, which is about to enter Phase-III in clinical trials.
Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.
An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.
More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.
The first low-cost version of the Shire ADHD drug benefits as a first-filer.
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.